Annual report pursuant to Section 13 and 15(d)

Subsequent Events (Details Narrative)

v3.22.1
Subsequent Events (Details Narrative)
$ in Millions
12 Months Ended
Mar. 04, 2022
USD ($)
Mar. 03, 2022
USD ($)
Feb. 11, 2022
shares
Nov. 19, 2021
ft²
Dec. 31, 2020
shares
Subsequent Event [Line Items]          
Conversion of Stock, Shares Issued         511,879
Aimmune Therapeutics Inc [Member]          
Subsequent Event [Line Items]          
Area of Land | ft²       4,500  
Lessee, Operating Sublease, Option to Extend       commencement date of January 1, 2022 and maturing on June 30, 2024  
Subsequent Event [Member]          
Subsequent Event [Line Items]          
Litigation Settlement, Expense | $ $ 425,000.0 $ 0.4      
Conversion of Stock, Shares Issued     60,855